Matthew Timpane, CMT
Senior Market Strategist,
Schaeffer's Investment Research
Matthew Timpane, CMT, is senior market strategist at Schaeffer's Investment Research. With over a decade of experience in finance, his areas of expertise include managing multi-strategy portfolios, trend-following, and trade execution efficiency. Mr. Timpane earned his B.S. in business from the University of Wisconsin.
Medical device maker Fulgent Genetics (FLGT) has received quite the revenue boost from NGS (Next-Generation Sequencing) surveillance, which is used to track coronavirus mutations that are integral to vaccine management, notes technical expert Matthew Timpane, CMT of Schaeffer's Investment Research.
Software stock Datadog (DDOG) recently broke out of a weekly flag pattern after quickly dipping below — and then regaining — its 20-week moving average, notes Matthew Timpane, technical expert and editor at Schaeffer's Investment Research.
California-based medical device maker Fulgent Genetics (FLGT) specializes in clinical diagnostic genetic sequencing, and was at the forefront of the coronavirus pandemic thanks to its RT-PCR COVID-19 test, notes Matthew Timpane, technical expert and editor at Schaeffer's Investment Research.
Jeans icon Levi Strauss (LEVI) has recently formed a cup and handle bottoming pattern on the charts, explains Matthew Timpane, a leading technical expert and analyst at Schaeffer's Investment Research.